• News Desk

Gilead targets two million remdesivir courses by year-end


Gilead Pharmaceutical company

(Reuters) - Gilead Sciences Inc expects supply of its potential COVID-19 drug remdesivir to exceed two million courses by year-end, the company said on Monday, more than double its previous target of 1 million.


The company also said it planned to start trials of an easier-to-use inhaled version of the antiviral drug, currently administered only intravenously, by August.


Remdesivir is at the forefront in the fight against the virus after the drug helped shorten hospital recovery times in a clinical trial. But producing and supplying billions of doses remain major concerns as the fast-spreading respiratory illness overwhelms healthcare systems around the world.


Read More...

amazon smile for pragnya.png
Our Non- Profit Partners
pragnya_logo.png
LOCAL EVENTS
BUSINESS NEWS
INDIA NEWS
BAY AREA NEWS

Powered by Studio M | 1917 Concourse Dr. San Jose CA 95131

  • Mediamahima